FDA puts CART-ddBCMA Phase 2 trial on hold after patient’s death
The U.S. Food and Drug Administration (FDA) has placed a hold on clinical testing of CART-ddBCMA, a cell therapy that Arcellx and Kite…
News
Phase 1b trial of STAR-LLD combo for myeloma approved by FDA
The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 1b trial to test STAR-LLD, Starton Therapeutics’ experimental continuous delivery…
FDA asked to extend Carvykti to myeloma patients after first relapse
Janssen is asking the U.S. Food and Drug Administration (FDA) to expand approval its cell therapy Carvykti (ciltacabtagene autoleucel) to allow for earlier…
Carvykti outperforms standard care as earlier line of therapy: Analysis
Carvykti (ciltacabtagene autoleucel) significantly reduces the risk of disease progression or death in adults with multiple myeloma who received one to three prior lines…
Gene therapy targeting T-cells shows promise in myeloma animal models
A gene therapy designed by Kelonia Therapeutics to work as an off-the-shelf or readily available CAR T-cell therapy for multiple myeloma showed early…
Sarclisa plus Kyprolis found to stop cancer for nearly 3 years in trial
Sarclisa (isatuximab), given on top of standard treatment with Kyprolis (carfilzomib) and the steroid dexamethasone, was found to delay disease progression by almost…
Dramatic gains in survival seen in myeloma since early 2000s: Analysis
Survival outcomes for people with multiple myeloma have improved substantially over the last two decades, likely due to the availability of new, more effective…
Positive early results seen for CAR T-cell therapy for myeloma in trial
Most patients with hard-to-treat multiple myeloma given NXC-201 — Nexcella’s experimental point-of-care CAR T-cell therapy — as part of a clinical trial in…
FDA joins EU and Japan in deciding if Abecma may treat RRMM earlier
The U.S. Food and Drug Administration (FDA) has agreed to review an application that, if approved, would allow the cell therapy Abecma (idecabtagene…
Adding Aphexda helps to collect more stem cells for ASCT in trial
Aphexda (formerly motixafortide), BioLineRx’s experimental add-on therapy, greatly increased the number of blood stem cells collected for autologous stem cell transplants (ASCT), a life-extending…
